J7313 HCPCS code: Injection, fluocinolone acetonide, intravitreal implant (iluvien), 0.01 mg
J7313 is the HCPCS Level II code for injection, fluocinolone acetonide, intravitreal implant (iluvien), 0.01 mg. In 2024 Medicare paid an average of $379.65 per service for J7313 across 17,330 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 38 per day on outpatient hospital claims. Medicare volume fell 18% from 2022 to 2024 (21,183 to 17,330 services). In 2024, about 359 clinicians billed Medicare for J7313 for 746 beneficiaries; Texas, Ohio, California accounted for 33% of services.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 2016-01-01 |
| Last action effective | 2019-10-01 |
Who bills J7313 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 359 |
| Medicare beneficiaries | 746 |
| States with claims | 24 |
| Share of services in top 3 states (Texas, Ohio, California) | 33% |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J7313, 2022–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2022 | 21,183 | 905 | $480.38 | $383.27 |
| 2023 | 20,454 | 867 | $475.26 | $378.73 |
| 2024 | 17,330 | 746 | $476.64 | $379.65 |
States with the most J7313 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| Texas | 2,186 | $381.62 |
| Ohio | 1,767 | $380.63 |
| California | 1,310 | $384.12 |
| Massachusetts | 855 | $384.18 |
| Florida | 817 | $375.22 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 38 | Anatomic Consideration |
| practitioner claims | 38 | Anatomic Consideration |
What changed for J7313
- 2016-01-01: J7313 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J7313?
J7313 is the HCPCS Level II code for injection, fluocinolone acetonide, intravitreal implant (iluvien), 0.01 mg. Short descriptor: "Inj., iluvien, 0.01 mg".
How much does Medicare pay for J7313?
In 2024, the average Medicare payment was $379.65 per service (average allowed $476.64).
Does Medicare cover J7313?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
How many units of J7313 can be billed per day?
38 on outpatient hospital claims; 38 on practitioner claims (NCCI medically unlikely edits).
Related J73 codes
- J7300 — Intrauterine copper contraceptive (paragard)
- J7301 — Levonorgestrel-releasing intrauterine contraceptive system (skyla), 13.5 mg
- J7302 — Levonorgestrel-releasing intrauterine contraceptive system, 52 mg
- J7303 — Contraceptive supply, hormone containing vaginal ring, each
- J7304 — Contraceptive supply, hormone containing patch, each
- J7306 — Levonorgestrel (contraceptive) implant system, including implants and supplies
- J7307 — Etonogestrel (contraceptive) implant system, including implant and supplies
- J7308 — Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg)
- J7309 — Methyl aminolevulinate (mal) for topical administration, 16.8%, 1 gram
- J7310 — Ganciclovir, 4.5 mg, long-acting implant
- J7311 — Injection, fluocinolone acetonide, intravitreal implant (retisert), 0.01 mg
- J7312 — Injection, dexamethasone, intravitreal implant, 0.1 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J7313
- Watch J7313 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J7313
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.